U.S. Faces Challenges in Maintaining Lead in Rare Disease Drug Development
A report by the National Security Commission on Emerging Biotechnology warns that the U.S. is losing its lead in rare disease drug development, posing a national security risk. The report highlights China's rapid progress in biotech innovation, driven by accelerated clinical trial pathways and active participant recruitment. The U.S. government's current policies focus more on curbing Chinese influence rather than bolstering domestic drug development. However, initiatives like the FDA's pilot program to improve clinical trial protocols aim to expedite drug development. The report calls for supportive policies to maintain U.S. competitiveness in this critical sector. 
